Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain
| Autor: | Lourdes Betegón Nicolás, Cristina Canal Fontcuberta, Gonzalo Barón Esquivias, Ginés Escolar Albaladejo, Carlos Rubio-Terrés, Marina de Salas-Cansado, Darío Rubio-Rodríguez, José Luis Zamorano |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Pyridones Cost effectiveness Cost-Benefit Analysis Drug Costs Risk Factors Internal medicine Atrial Fibrillation medicine Humans Stroke Aged 80 and over Acenocoumarol business.industry Incidence Warfarin Anticoagulants Atrial fibrillation General Medicine Cost-effectiveness analysis medicine.disease Models Economic Spain Cohort Emergency medicine Cardiology Pyrazoles Female Apixaban business medicine.drug |
| Zdroj: | Revista Española de Cardiología (English Edition). 68:680-690 |
| ISSN: | 1885-5857 |
| DOI: | 10.1016/j.rec.2014.08.010 |
| Popis: | Introduction and objectives Cost-effectiveness analysis of apixaban (5 mg twice daily) vs acenocoumarol (5 mg/day) in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Methods Markov model covering the patient's entire lifespan with 10 health states. Data on the efficacy and safety of the drugs were provided by the ARISTOTLE trial. Warfarin and acenocoumarol were assumed to have therapeutic equivalence. Perspectives: The Spanish National Health System and society. Information on the cost of the drugs, complications, and the management of the disease was obtained from Spanish sources. Results In a cohort of 1000 patients with nonvalvular atrial fibrillation, administration of apixaban rather than acenocoumarol would avoid 18 strokes, 71 hemorrhages (28 intracranial or major), 2 myocardial infarctions, 1 systemic embolism, and 23 related deaths. Apixaban would prolong life (by 0.187 years) and result in more quality-adjusted life years (by 0.194 years) per patient. With apixaban, the incremental costs for the Spanish National Health System and for society would be € 2488 and € 1826 per patient, respectively. Consequently, the costs per life year gained would be € 13 305 and € 9765 and the costs per quality-adjusted life year gained would be € 12 825 and € 9412 for the Spanish National Health System and for society, respectively. The stability of the baseline case was confirmed by sensitivity analyses. Conclusions According to this analysis, apixaban may be cost-effective in the prevention of stroke in patients with nonvalvular atrial fibrillation compared with acenocoumarol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect